The estimated Net Worth of Vikram Malik is at least $6.07 Million dollars as of 3 June 2024. Mr. Malik owns over 7,500 units of Evolus Inc stock worth over $3,764,269 and over the last 7 years he sold EOLS stock worth over $2,085,219. In addition, he makes $221,698 as Chairman of the Board at Evolus Inc.
Sign up
Mr. Malik EOLS stock SEC Form 4 insiders trading
Vikram has made over 9 trades of the Evolus Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 7,500 units of EOLS stock worth $97,200 on 3 June 2024.
The largest trade he's ever made was buying 1,298,701 units of Evolus Inc stock on 3 June 2019 worth over $24,999,994. On average, Vikram trades about 98,857 units every 128 days since 2018. As of 3 June 2024 he still owns at least 246,514 units of Evolus Inc stock.
You can see the complete history of Mr. Malik stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vikram Malik biography
Vikram Malik serves as Chairman of the Board of the Company. Mr. Malik has served as a member of ALPHAEON’s board of directors since April 2014. Since May 2013, Mr. Malik has served as the Managing Partner of SCH. From August 2011 to May 2013, Mr. Malik served as Vice Chairman Investment Banking for Deutsche Bank Securities, Inc. From November 2010 to August 2011, Mr. Malik served as a Managing Director in the Healthcare Corporate and Investment Banking Group of Merrill Lynch, Pierce, Fenner & Smith Incorporated. From June 2000 to November 2010, Mr. Malik served as the Managing Director of Banc of America Securities, LLC. Mr. Malik received a B.A. in Economics from Delhi University and an M.B.A. from Boston University Graduate School of Management.
What is the salary of Vikram Malik?
As the Chairman of the Board of Evolus Inc, the total compensation of Vikram Malik at Evolus Inc is $221,698. There are 9 executives at Evolus Inc getting paid more, with Michael Jafar having the highest compensation of $3,929,160.
How old is Vikram Malik?
Vikram Malik is 57, he's been the Chairman of the Board of Evolus Inc since 2018. There are 6 older and 5 younger executives at Evolus Inc. The oldest executive at Evolus Inc is Peter Farrell, 78, who is the Independent Director.
What's Vikram Malik's mailing address?
Vikram's mailing address filed with the SEC is 520 Newport Center Dr #1200, Newport Beach, CA 92660, USA.
Insiders trading at Evolus Inc
Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox und 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.
What does Evolus Inc do?
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
What does Evolus Inc's logo look like?
Complete history of Mr. Malik stock trades at Evolus Inc
Evolus Inc executives and stock owners
Evolus Inc executives and other stock owners filed with the SEC include:
-
Michael Jafar,
Chief Commercial Officer -
David Moatazedi,
President, Chief Executive Officer, Director -
Rui Avelar,
Chief Medical Officer, Head of Research & Development -
David Moatazedi,
Pres, CEO & Director -
Lauren Silvernail,
Chief Financial Officer, Executive Vice President - Corporate Development -
Lauren P. Silvernail,
CFO & Exec. VP of Corp. Devel. -
Dr. Rui Avelar Dip.SportMed, M.D., C.CFP,
Chief Medical Officer and Head of R&D -
Karah Parschauer,
Independent Director -
Peter Farrell,
Independent Director -
Vikram Malik,
Chairman of the Board -
David Gill,
Independent Director -
Robert Hayman,
Independent Director -
Simone Blank,
Director -
Tram Bui,
IR Contact Officer -
Jeff Plumer,
General Counsel -
Jessica Novak,
Sr. VP of HR -
Crystal Muilenburg,
Chief Marketing Officer -
Kurt Knab,
VP of Sales -
Jeffrey J. Plumer,
Gen. Counsel -
David K. Erickson,
VP of Investor Relations -
Biopharma, Inc. Aeon,
-
Sandra Beaver,
Chief Financial Officer -
Crystal Muilenburg,
Chief Marketing Officer -
Albert G Iii White,
Director -
Kristine Romine,
Director -
Bosun Hau,
Director -
1 Llc Alphaeon,
-
Brady Stewart,
Director -
Tomoko Yamagishi Dressler,
Chief Marketing Officer -
Inc. Medytox,